Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. The agreement covers PNT2002, a ...

Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a challenge to Astellas’ first ...

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

This month’s executive moves span a diverse range of organisations – from CDMOs and genomics platforms to diagnostics and ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

Scancell is using a new service launched by the NHS to pair patients with suitable clinical trials in a phase 2 trial of its melanoma cancer vaccine.

If you are middle aged and find you have to hold your phone at arm's length to read, you may have presbyopia - a difficulty focusing on close objects that is usually corrected using glasses ...

Robin Walsh takes a look back at the origins of the industry in the 19th century and its ongoing evolution ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

New data on Sarepta's gene therapy for Duchenne muscular dystrophy (DMD) has gone a long way towards building confidence in its efficacy – but have introduced a concern about its safety.

Ampio Pharma's candidate therapy for knee osteoarthritis has been knocked back by the FDA, which will likely now require a new clinical trial of the drug before it will consider a review. Shares ...